M
Michael G. Hanna
Researcher at University College London
Publications - 607
Citations - 32703
Michael G. Hanna is an academic researcher from University College London. The author has contributed to research in topics: Atrial fibrillation & Apixaban. The author has an hindex of 77, co-authored 573 publications receiving 28060 citations. Previous affiliations of Michael G. Hanna include University of London & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more
TL;DR: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Journal ArticleDOI
Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE study
Álvaro Avezum,Renato D. Lopes,Philip Schulte,Fernando Lanas,Michael G. Hanna,Prem Pais,Çetin Erol,Rafael Diaz,Christopher B. Granger,John H. Alexander +9 more
TL;DR: Pts with AF and VHD are at high risk for thromboembolic events and bleeding, and apixaban was similarly efficacious and safe in AF pts with and without VHD.
Journal ArticleDOI
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Stefan H. Hohnloser,Ziad Hijazi,Laine Thomas,John H. Alexander,John Amerena,Michael G. Hanna,Matyas Keltai,Fernando Lanas,Renato D. Lopes,Jose Lopez-Sendon,Christopher B. Granger,Lars Wallentin +11 more
TL;DR: In patients with AF, renal impairment was associated with increased risk of cardiovascular events and bleeding, and apixaban treatment reduced the rate of stroke, death, and major bleeding, regardless of renal function.
Journal ArticleDOI
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial
Jan B. Vermorken,Anke M. E. Claessen,Harm van Tinteren,Helen Gall,Renate Ezinga,Sybren L. Meijer,Rik J. Scheper,Chris J.L.M. Meijer,Elizabeth Bloemena,Janet H. Ransom,Michael G. Hanna,Herbert M. Pinedo +11 more
TL;DR: ASI gave significant clinical benefit in surgically resected patients with stage II colon cancer and should be considered in the management of stage II Colon cancer.
Journal ArticleDOI
Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale
Renato D. Lopes,John H. Alexander,Sana M. Al-Khatib,Jack Ansell,Raphael Diaz,J. Donald Easton,Bernard J. Gersh,Christopher B. Granger,Michael G. Hanna,John D. Horowitz,Elaine M. Hylek,John J.V. McMurray,Freek W.A. Verheugt,Lars Wallentin +13 more
TL;DR: The primary objective of ARISTOTLE is to determine if the factor Xa inhibitor, apixaban, is noninferior to warfarin at reducing the combined endpoint of stroke (ischemic or hemorrhagic) and systemic embolism in patients with AF and at least 1 additional risk factor for stroke.